Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

Naval Daver, Jayastu Senapati, Abhishek Maiti, Sanam Loghavi, Tapan M. Kadia, Courtney D. DiNardo, Naveen Pemmaraju, Elias Jabbour, Guillermo Montalban‐Bravo, Guilin Tang, Koji Sasaki, Gautam Borthakur, Musa Yılmaz, Joie Alvarez, Sherry Pierce, Graciela M. Nogueras‐González, Jing Ning, Ghayas C. Issa, Michael Andreeff, Hussein A. Abbas, Farhad Ravandi, Guillermo Garcia‐Manero, Hagop M. Kantarjian